Anixa reports stable disease after 90 days in ovarian cancer CAR-T study
Anixa reported stable disease after 90 days in a patient participating in its CAR-T study for ovarian cancer.
Anixa reported stable disease after 90 days in a patient participating in its CAR-T study for ovarian cancer.